source
- Eli Lilly removes Gaucher disease gene therapy trial from pipeline, citing unmet internal criteriaEli Lilly has announced the removal of a phase 1/2 study testing its GBA1 gene therapy for Gaucher disease type 1. The program was part of the assets acquired when the company bought Prevail Therap…
- Pathos AI acquires bispecific ADC from Alphamab and secures AstraZeneca partnershipPathos AI announced it will pay $125 million upfront for the rights to JSKN016, a bispecific TROP2/HER3 antibody‑drug conjugate from China’s Alphamab Oncology. The agreement also includes up to $2.…